Prothena Corporation PLC
NASDAQ:PRTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Prothena Corporation PLC
Stock-Based Compensation
Prothena Corporation PLC
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prothena Corporation PLC
NASDAQ:PRTA
|
Stock-Based Compensation
$37.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Alkermes Plc
NASDAQ:ALKS
|
Stock-Based Compensation
$98.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
Amarin Corporation PLC
NASDAQ:AMRN
|
Stock-Based Compensation
$13.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
0%
|
|
|
M
|
Mural Oncology PLC
NASDAQ:MURA
|
Stock-Based Compensation
$5.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Prothena Corporation PLC
Glance View
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
See Also
What is Prothena Corporation PLC's Stock-Based Compensation?
Stock-Based Compensation
37.6m
USD
Based on the financial report for Dec 31, 2025, Prothena Corporation PLC's Stock-Based Compensation amounts to 37.6m USD.
What is Prothena Corporation PLC's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
14%
Over the last year, the Stock-Based Compensation growth was -18%. The average annual Stock-Based Compensation growth rates for Prothena Corporation PLC have been 6% over the past three years , 11% over the past five years , and 14% over the past ten years .
